| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/13/2023 | -22.28% | B of A Securities | $32 → $3 | Downgrades | Buy → Underperform |
| 08/24/2023 | 392.23% | Morgan Stanley | $22 → $19 | Maintains | Equal-Weight |
| 08/17/2023 | 651.3% | RBC Capital | → $29 | Reiterates | Outperform → Outperform |
| 08/17/2023 | — | CL King | Initiates Coverage On | → Neutral | |
| 08/03/2023 | 469.95% | Morgan Stanley | $23 → $22 | Maintains | Equal-Weight |
| 05/31/2023 | 495.85% | Morgan Stanley | $27 → $23 | Maintains | Equal-Weight |
| 05/15/2023 | 651.3% | RBC Capital | → $29 | Reiterates | Outperform → Outperform |
| 05/04/2023 | 651.3% | RBC Capital | $32 → $29 | Maintains | Outperform |
| 01/06/2023 | 599.48% | Morgan Stanley | $17 → $27 | Maintains | Equal-Weight |
| 11/11/2022 | 495.85% | RBC Capital | → $23 | Initiates Coverage On | → Outperform |
| 11/10/2022 | 340.41% | Morgan Stanley | $19 → $17 | Maintains | Equal-Weight |
| 11/09/2022 | 651.3% | Goldman Sachs | $34 → $29 | Maintains | Buy |
| 10/11/2022 | 392.23% | Morgan Stanley | $22 → $19 | Maintains | Equal-Weight |
| 08/03/2022 | 780.83% | Goldman Sachs | $48 → $34 | Maintains | Buy |
| 08/02/2022 | 469.95% | Morgan Stanley | $20 → $22 | Maintains | Equal-Weight |
| 07/18/2022 | 521.76% | Stifel | $30 → $24 | Maintains | Buy |
| 07/14/2022 | 418.13% | Morgan Stanley | $48 → $20 | Downgrades | Overweight → Equal-Weight |
| 06/14/2022 | 754.92% | Cowen & Co. | $60 → $33 | Maintains | Outperform |
| 06/14/2022 | 677.2% | Stifel | $55 → $30 | Maintains | Buy |
| 05/05/2022 | 1143.52% | Morgan Stanley | $50 → $48 | Maintains | Overweight |
| 05/05/2022 | 1324.87% | SVB Leerink | $65 → $55 | Maintains | Outperform |
| 08/18/2021 | 1713.47% | Cowen & Co. | → $70 | Initiates Coverage On | → Outperform |
| 08/09/2021 | 1324.87% | Morgan Stanley | $60 → $55 | Maintains | Equal-Weight |
| 05/06/2021 | 1454.4% | Morgan Stanley | $58 → $60 | Maintains | Equal-Weight |
| 04/19/2021 | 1532.12% | Wells Fargo | → $63 | Initiates Coverage On | → Overweight |
| 03/10/2021 | 1402.59% | Morgan Stanley | $52 → $58 | Maintains | Equal-Weight |
| 12/16/2020 | — | Oppenheimer | Initiates Coverage On | → Perform | |
| 12/15/2020 | 1247.15% | Morgan Stanley | $48 → $52 | Maintains | Equal-Weight |
| 10/12/2020 | 1454.4% | SVB Leerink | → $60 | Initiates Coverage On | → Outperform |
| 10/12/2020 | 1298.96% | Stifel | → $54 | Initiates Coverage On | → Buy |
| 10/12/2020 | 1143.52% | Morgan Stanley | → $48 | Initiates Coverage On | → Equal-Weight |
What is the target price for Outset Medical (OM)?
The latest price target for Outset Medical (NASDAQ: OM) was reported by B of A Securities on October 13, 2023. The analyst firm set a price target for $3.00 expecting OM to fall to within 12 months (a possible -22.28% downside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Outset Medical (OM)?
The latest analyst rating for Outset Medical (NASDAQ: OM) was provided by B of A Securities, and Outset Medical downgraded their underperform rating.
When is the next analyst rating going to be posted or updated for Outset Medical (OM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Outset Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Outset Medical was filed on October 13, 2023 so you should expect the next rating to be made available sometime around October 13, 2024.
Is the Analyst Rating Outset Medical (OM) correct?
While ratings are subjective and will change, the latest Outset Medical (OM) rating was a downgraded with a price target of $32.00 to $3.00. The current price Outset Medical (OM) is trading at is $3.86, which is out of the analyst's predicted range.